FDA Peptide Reclassification 2026: What It Means for Patients
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
Regulatory News
104 stories across all digests
Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
FDA Approves New F8 Formulation of Tesamorelin for HIV Lipodystrophy
The FDA approved a new formulation of tesamorelin, the only approved treatment for HIV-associated excess abdominal fat, representing continued investment in peptide therapeutics for rare conditions.
BPC-157 Regulatory Status: FDA Category 2 Explainer and Potential Reclassification
Updated explainer clarifying BPC-157 is not outright banned but in Category 2 requiring further investigation. Discusses potential shifts after public statements about moving peptides back to Category 1.
FDA Holds Historic Meeting on Allowing Peptides as Dietary Supplement Ingredients
The FDA held a public meeting to discuss broadening supplement ingredient criteria to include peptides, probiotics, and other substances. This is the first such meeting since RFK Jr. became HHS Secretary.
FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis
J&J's icotrokinra (Icotyde) approved for moderate-to-severe plaque psoriasis, with ~70% of patients achieving clear or almost clear skin by week 16.
RFK Jr. Signals FDA Will Deregulate ~14 Peptides Including BPC-157 and Ipamorelin
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular and Stroke Benefits
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.
UK MPs Hear Warnings: Black Market GLP-1 Profits Rival Cocaine
The MHRA told Parliament that 81,000 doses have been seized in three years, with illegal GLP-1 profit margins rivaling class A drugs.
FDA Grants Survodutide Breakthrough Therapy Designation for MASH
The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.
IMCIVREE Wins FDA Approval for Acquired Hypothalamic Obesity
FDA approved setmelanotide (IMCIVREE), an MC4R agonist peptide, for reducing body weight in adults and children aged 4+. Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks.
FDA Approves Higher 2 mg Dose of Ozempic for Type 2 Diabetes
The FDA approved a new 2 mg dose of Ozempic (semaglutide) injection, providing an additional option for patients needing more intensive glycemic management.
Compounded GLP-1 Prescriptions Keep Rising Despite FDA Crackdown
Healthcare Brew reports that despite the FDA sending thousands of warning letters since September 2025, compounded semaglutide and tirzepatide prescriptions have increased since the semaglutide shortage ended in February 2025. About 80% of compounded GLP-1 prescriptions now include supplemental ingredients like B vitamins to avoid being classified as exact copies of FDA-approved drugs.
Washington Post Editorial: RFK Jr.'s Peptide Advocacy Is 'Hypocritical Quackery'
The Washington Post editorial board published a sharp critique of Health Secretary Kennedy, arguing that his insistence on rigorous evidence for vaccines while simultaneously pushing the FDA to deregulate peptides with minimal human safety data represents a dangerous double standard in public health policy.
GLP-1 Lawsuits Surpass 3,500 Pending Cases as Vision Loss Claims Surge
Over 3,546 lawsuits are now consolidated in two federal MDLs — one for gastroparesis and one for NAION vision loss. On March 3, a federal judge appointed lead counsel for the NAION MDL. Studies show semaglutide users face a fourfold increase in NAION risk, with vision loss claims now generating more legal attention than earlier gastroparesis cases.